The Influences of Symbiotic Host Gut Microbiota During Obesity and Diabetes

S Ranhotra, Harmit

doi:10.18502/ijdo.v17i1.18035

Volume 17, Issue 1 (2-2025) IJDO 2025, 17(1): 61-75 | Back to browse issues page

‎ 10.18502/ijdo.v17i1.18035

Mendeley

Zotero

RefWorks

S Ranhotra H. The Influences of Symbiotic Host Gut Microbiota During Obesity and Diabetes. IJDO 2025; 17 (1) :61-75
URL: http://ijdo.ssu.ac.ir/article-1-936-en.html

The Influences of Symbiotic Host Gut Microbiota During Obesity and Diabetes

Harmit S Ranhotra ^*

Department of Biochemistry, St. Edmund’s College, Shillong 793 003, India

Abstract: (63 Views)

The resident gut microbiota is a complex and dynamic entity and at times their imbalance (dysbiosis) can trigger the onset of diseases. Dysbiosis are known to be correlated to host metabolic disease, liver disease, immune complications amongst few others. Dysbiosis can deregulate the biosynthesis and secretion of metabolites by the microbiota which is normally considered beneficial to the host. Altered metabolites availability can modulate host organs/tissues functions which may influence certain disease onset and progression. Obesity and diabetes are diseases that exhibits a correlation with significant change in gut microbiota composition and diversity. Modulation in the secretion of gut microbiota-derived metabolites during dysbiosis appears to influence the onset and progression of obesity and diabetes. However, direct physiological link between the gut microbiota and obesity and diabetes is not confirmed yet and remains a challenge for further investigations. In this article, findings where by perturbation of the gut microbiota may contribute towards obesity and diabetes in the host are reviewed.

Keywords: Dysbiosis, Gut, Metabolites, Metabolic disorders

Full-Text [PDF 744 kb] (35 Downloads)

Type of Study: Research | Subject: Special
Received: 2024/11/7 | Accepted: 2025/01/20 | Published: 2025/02/27

References

1. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nature reviews immunology. 2016;16(6):341-52.

2. Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. The FEBS journal. 2020;287(5):833-55.

3. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nature microbiology. 2017;2(5):1-7.

4. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844-54.

5. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nature Reviews Microbiology. 2023;21(11):719-33.

6. Sarkar SR, Banerjee S. Gut microbiota in neurodegenerative disorders. Journal of neuroimmunology. 2019;328:98-104.

7. Shapiro H, Thaiss CA, Levy M, Elinav E. The cross talk between microbiota and the immune system: metabolites take center stage. Current opinion in immunology. 2014;30:54-62.

8. Kim CH. Immune regulation by microbiome metabolites. Immunology. 2018 Jun;154(2):220-9.

9. Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014;41(2):296-310.

10. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC microbiology. 2011;11:1-2.

11. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell host & microbe. 2007;2(2):119-29.

12. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Current opinion in immunology. 2011;23(4):473-80.

13. Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cellular and Molecular Life Sciences. 2017;74:2959-77.

14. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacological research. 2013;69(1):52-60.

15. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. nature. 2006;444(7122):1022-3.

16. Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, et al. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC gastroenterology. 2015;15:1-0.

17. Liu X, Blouin JM, Santacruz A, Lan A, Andriamihaja M, Wilkanowicz S, et al. High-protein diet modifies colonic microbiota and luminal environment but not colonocyte metabolism in the rat model: the increased luminal bulk connection. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2014;307(4):G459-70.

18. Alemany M. The problem of nitrogen disposal in the obese. Nutrition research reviews. 2012;25(1):18-28.

19. Asl SZ, Ghasemi A, Azizi F. Serum nitric oxide metabolites in subjects with metabolic syndrome. Clinical biochemistry. 2008;41(16-17):1342-7.

20. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome medicine. 2016;8:1-2.

21. Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. Current obesity reports. 2019;8:317-32.

22. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology. 2021;19(1):55-71.

23. Pedersen R, Ingerslev HC, Sturek M, Alloosh M, Cirera S, Christoffersen BØ, et al. Characterisation of gut microbiota in Ossabaw and Göttingen minipigs as models of obesity and metabolic syndrome. PloS one. 2013;8(2):e56612.

24. Hansen AK, Hansen CH, Krych L, Nielsen DS. Impact of the gut microbiota on rodent models of human disease. World journal of gastroenterology: WJG. 2014;20(47):17727-17736.

25. Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS letters. 2014;588(22):4223-33.

26. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18(1):190-5.

27. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell host & microbe. 2008;3(4):213-23.

28. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences. 2007;104(3):979-84.

29. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-6.

30. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflammatory bowel diseases. 2016;22(5):1137-50.

31. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clinical & Experimental Immunology. 2015;179(3):363-77.

32. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell. 2014;159(4):789-99.

33. Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell metabolism. 2015;22(3):516-30.

34. O'Connor A, Quizon PM, Albright JE, Lin FT, Bennett BJ. Responsiveness of cardiometabolic-related microbiota to diet is influenced by host genetics. Mammalian Genome. 2014;25(11):583-99.

35. Davenport ER, Cusanovich DA, Michelini K, Barreiro LB, Ober C, Gilad Y. Genome-wide association studies of the human gut microbiota. PloS one. 2015;10(11):e0140301.

36. Bhat MI, Kapila R. Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. Nutrition reviews. 2017;75(5):374-89.

37. Krautkramer KA, Kreznar JH, Romano KA, Vivas EI, Barrett-Wilt GA, Rabaglia ME, et al. Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Molecular cell. 2016;64(5):982-92.

38. Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839-49.

39. Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, et al. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. MBio. 2014;5(4):10-128.

40. Remely M, Lovrecic L, De La Garza AL, Migliore LU, Peterlin B, Milagro FI, et al. Therapeutic perspectives of epigenetically active nutrients. British journal of pharmacology. 2015;172(11):2756-68.

41. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. nature. 2006;444(7122):1027-31.

42. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.

43. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500(7464):585-8.

44. Tims S, Derom C, Jonkers DM, Vlietinck R, Saris WH, Kleerebezem M, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. The ISME journal. 2013;7(4):707-17.

45. Gophna U, Konikoff T, Nielsen HB. Oscillospira and related bacteria-From metagenomic species to metabolic features. Environmental microbiology. 2017;19(3):835-41.

46. Miller TL, Wolin MJ, De Macario EC, Macario A. Isolation of Methanobrevibacter smithii from human feces. Applied and environmental microbiology. 1982;43(1):227-32.

47. Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, et al. Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition. Cell host & microbe. 2019;26(2):252-64.

48. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. The American journal of clinical nutrition. 2011;94(1):58-65.

49. Gao X, Lin SH, Ren F, Li JT, Chen JJ, Yao CB, et al. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nature communications. 2016;7(1):1-4. [DOI:10.1038/ncomms100]

50. Lin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PloS one. 2012;7(4):e35240.

51. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell metabolism. 2009;10(3):167-77.

52. Spinelli V, Lalloyer F, Baud G, Osto E, Kouach M, Daoudi M, et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. International journal of obesity. 2016;40(8):1260-7.

53. MacDonald MJ, Fahien LA, Mertz RJ, Rana RS. Effect of esters of succinic acid and other citric acid cycle intermediates on insulin release and inositol phosphate formation by pancreatic islets. Archives of biochemistry and biophysics. 1989;269(2):400-6.

54. Mills EL, Pierce KA, Jedrychowski MP, Garrity R, Winther S, Vidoni S, et al. Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature. 2018;560(7716):102-6.

55. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell. 2007;131(2):242-56.

56. Hajer GR, Van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European heart journal. 2008;29(24):2959-71.

57. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the national academy of sciences. 2004;101(44):15718-23.

58. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. nature. 2011;472(7341):57-63.

59. Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreo U, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proceedings of the National Academy of Sciences. 2011;108(22):9232-7.

60. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474(7353):649-53.

61. Virtue AT, McCright SJ, Wright JM, Jimenez MT, Mowel WK, Kotzin JJ, et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Science translational medicine. 2019;11(496):eaav1892.

62. Assmann TS, Cuevas-Sierra A, Riezu-Boj JI, Milagro FI, Martínez JA. Comprehensive analysis reveals novel interactions between circulating MicroRNAs and gut microbiota composition in human obesity. International journal of molecular sciences. 2020 Dec 14;21(24):9509.

63. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell. 2004;116(2):281-97.

64. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?. Diabetologia. 2006;49:2105-8.

65. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455(7216):1109-13.

66. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, et al. Lactobacillus johnsonii N6. 2 mitigates the development of type 1 diabetes in BB-DP rats. Plos one. 2010;5(5):e10507.

67. Roesch LF, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. The ISME journal. 2009;3(5):536-48.

68. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC medicine. 2013;11:1-2.

69. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. Toward defining the autoimmune microbiome for type 1 diabetes. The ISME journal. 2011;5(1):82-91.

70. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nature Reviews Endocrinology. 2016;12(3):154-67.

71. Allin KH, Nielsen T, Pedersen O. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus. European journal of endocrinology. 2015;172(4):R167-77.

72. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes care. 2011;34(2):392-7.

73. Velloso LA, Folli F, Saad MJ. TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocrine reviews. 2015;36(3):245-71.

74. Gülden E, Ihira M, Ohashi A, Reinbeck AL, Freudenberg MA, Kolb H, et al. Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice. PloS one. 2013;8(9):e75385.

75. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005;48:1565-75.

76. Tai N, Peng J, Liu F, Gulden E, Hu Y, Zhang X, et al. Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice. Journal of Experimental Medicine. 2016;213(10):2129-46.

77. Yu F, Han W, Zhan G, Li S, Jiang X, Wang L, et al. Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice. Aging (Albany NY). 2019;11(22):10454.

78. Vangipurapu J, Fernandes Silva L, Kuulasmaa T, Smith U, Laakso M. Microbiota-related metabolites and the risk of type 2 diabetes. Diabetes care. 2020;43(6):1319-25.

79. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72.

80. Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 2007;292(3):E740-7.

81. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. nature. 2012;490(7418):55-60.

82. Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Frontiers in pharmacology. 2018;9:1382.

83. Chambers ES, Morrison DJ, Frost G. Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?. Proceedings of the Nutrition Society. 2015;74(3):328-36.

84. Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell host & microbe. 2018;23(6):705-15.

85. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1):84-96.

86. Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World Journal of Gastroenterology. 2013;19(43):7620.

87. Arany Z, Neinast M. Branched chain amino acids in metabolic disease. Current Diabetes Reports. 2018;18:1-8.

88. Zhou M, Shao J, Wu CY, Shu L, Dong W, Liu Y, et al. Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes. 2019;68(9):1730-46.

89. Dehghan P, Farhangi MA, Nikniaz L, Nikniaz Z, Asghari‐Jafarabadi M. Gut microbiota‐derived metabolite trimethylamine N‐oxide (TMAO) potentially increases the risk of obesity in adults: An exploratory systematic review and dose‐response meta‐analysis. Obesity Reviews. 2020;21(5):e12993.

90. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine. 2013;19(5):576-85.

91. Comai S, Bertazzo A, Brughera M, Crotti S. Tryptophan in health and disease. Advances in clinical chemistry. 2020;95:165-218.

92. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-76.

93. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell host & microbe. 2018;23(6):716-24.

94. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell metabolism. 2018;28(5):737-49.

95. Taleb S. Tryptophan dietary impacts gut barrier and metabolic diseases. Frontiers in immunology. 2019;10:2113.

96. Koh A, Molinaro A, Stahlman M, Khan MT, Schmidt C, Manneras-Holm L, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947-61.

97. Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nature Communications. 2020;11(1):5881. [DOI:10.1038/s41467-020-20412-9]